Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

PMID:
28576927
2.

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.

Chang ZL, Chen YY.

Trends Mol Med. 2017 May;23(5):430-450. doi: 10.1016/j.molmed.2017.03.002. Epub 2017 Apr 13. Review.

PMID:
28416139
3.

Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, Feng JF.

Biosci Rep. 2017 Jan 27;37(1). pii: BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Review.

4.

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.

PLoS One. 2016 Dec 1;11(12):e0166891. doi: 10.1371/journal.pone.0166891. eCollection 2016. Erratum in: PLoS One. 2017 Feb 15;12 (2):e0172640.

5.

Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Rengstl B, Schmid F, Weiser C, Döring C, Heinrich T, Warner K, Becker PS, Wistinghausen R, Kameh-Var S, Werling E, Billmeier A, Seidl C, Hartmann S, Abken H, Küppers R, Hansmann ML, Newrzela S.

Oncoimmunology. 2016 Mar 16;5(6):e1160186. doi: 10.1080/2162402X.2016.1160186. eCollection 2016 Jun.

6.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN.

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

7.

Recent advances in the management of Hodgkin lymphoma.

Villasboas JC, Ansell SM.

F1000Res. 2016 Apr 27;5. pii: F1000 Faculty Rev-768. doi: 10.12688/f1000research.8301.1. eCollection 2016. Review.

8.

Strategies to genetically engineer T cells for cancer immunotherapy.

Spear TT, Nagato K, Nishimura MI.

Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2. Review.

9.

Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Hombach AA, Görgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, Abken H.

Mol Ther. 2016 Aug;24(8):1423-34. doi: 10.1038/mt.2016.82. Epub 2016 Apr 26.

10.

The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.

Nagle SJ, Garfall AL, Stadtmauer EA.

Cancer J. 2016 Jan-Feb;22(1):27-33. doi: 10.1097/PPO.0000000000000166. Review.

11.

Novel immunotherapies in lymphoid malignancies.

Batlevi CL, Matsuki E, Brentjens RJ, Younes A.

Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Review.

12.

Adoptive T-Cell Immunotherapy.

Gottschalk S, Rooney CM.

Curr Top Microbiol Immunol. 2015;391:427-54. doi: 10.1007/978-3-319-22834-1_15. Review.

13.

Challenges and opportunities of allogeneic donor-derived CAR T cells.

Yang Y, Jacoby E, Fry TJ.

Curr Opin Hematol. 2015 Nov;22(6):509-515. doi: 10.1097/MOH.0000000000000181. Review.

14.

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.

Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, Thomas SH, Brown CE, La Rosa C, Diamond DJ, Jensen MC, Nakamura R, Zaia JA, Forman SJ.

Clin Cancer Res. 2015 Jul 1;21(13):2993-3002. doi: 10.1158/1078-0432.CCR-14-2920. Epub 2015 Apr 2.

15.

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Wang X, Rivière I.

Cancer Gene Ther. 2015 Mar;22(2):85-94. doi: 10.1038/cgt.2014.81. Epub 2015 Feb 27. Review.

16.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.

Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G.

Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17.

17.

Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.

Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ.

Blood. 2014 Oct 16;124(16):2514-22. doi: 10.1182/blood-2014-01-553362. Epub 2014 Sep 2.

18.

Genetically modified T-cell therapy for osteosarcoma.

DeRenzo C, Gottschalk S.

Adv Exp Med Biol. 2014;804:323-40. doi: 10.1007/978-3-319-04843-7_18. Review.

19.

CD19-CAR trials.

Ramos CA, Savoldo B, Dotti G.

Cancer J. 2014 Mar-Apr;20(2):112-8. doi: 10.1097/PPO.0000000000000031. Review.

20.

Cellular immune therapy for viral infections in transplant patients.

Khanna R, Smith C.

Indian J Med Res. 2013 Nov;138(5):796-807. Review.

Supplemental Content

Support Center